2. Autophagy Apoptosis Epigenetics Cell Cycle/DNA Damage MAPK/ERK Pathway Stem Cell/Wnt NF-κB
  3. Autophagy Caspase Bcl-2 Family PARP p38 MAPK ERK NF-κB Apoptosis
  4. Peiminine

Peiminine  (Synonyms: Verticinone; Raddeanine)

Cat. No.: HY-N0213 Purity: 99.94%
COA Handling Instructions

Molarity Calculator

Peiminine is a compound that can be isolated from Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family). Peiminine can induce apoptosis in human hepatocellular carcinoma HepG2 cells through both extrinsic and intrinsic apoptotic pathways. Peiminine has anti-inflammatory, anticancer, anti-osteoporosis, cardioprotective and other activities in many animal models.

For research use only. We do not sell to patients.

Peiminine Chemical Structure

Peiminine Chemical Structure

CAS No. : 18059-10-4

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 94 In-stock
Solution
10 mM * 1 mL in DMSO USD 94 In-stock
Solid
1 mg USD 40 In-stock
5 mg USD 86 In-stock
10 mg USD 134 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Peiminine Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

View All PARP Isoform Specific Products:

View All Isoforms
PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Peiminine is a compound that can be isolated from Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family). Peiminine can induce apoptosis in human hepatocellular carcinoma HepG2 cells through both extrinsic and intrinsic apoptotic pathways. Peiminine has anti-inflammatory, anticancer, anti-osteoporosis, cardioprotective and other activities in many animal models[1][2][3][4][5][6].

IC50 & Target

Caspase 3

 

Caspase-8

 

Caspase-9

 

PARP-1

 

ERK1

 

ERK2

 

Bcl-2

 

p65

 

In Vitro

Peiminine (2-6 μg/mL, 24 h) decreases the expressions of procaspase-3, procaspases-8 and -9 and increases the levels of caspase-3, 8, 9 protein in HepG2 cells[1].
Peiminine (2-14 μg/mL, 24-72 h) displays the marked cytotoxicity to HepG2, Hela, SW480 and MCF-7 cells[1].
Peiminine (2-6 μg/mL, 24 h) induces apoptosis in HepG2 cells[1].
Peiminine (2-6 μg/mL, 24 h) induces HepG2 cells arrest at the G2/M phase[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peiminine Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: HepG2, Hela, SW480, MCF-7
Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL, 10 μg/mL, 12μg/mL, and 14 μg/mL
Incubation Time: 24 h, 48 h, 72 h
Result: Exhibited a significant inhibition on the survival of HepG2, Hela, SW480 and MCF-7 cells with the IC50 values were 4.58, 4.89, 5.07 and 5.12 μg/mL at 24 h, respectively.

Apoptosis Analysis[1]

Cell Line: HepG2
Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL
Incubation Time: 24 h
Result: Dissociated chromosome to produce DNA fragments dose-dependently.

Cell Cycle Analysis[1]

Cell Line: HepG2
Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL
Incubation Time: 24 h
Result: Decreased the percentage of G1 phases from 65.15% ± 0.78 to 49.55% ± 0.17 with the increase of concentrations.
Increased the percentage of G2/M phases from 17.32% ± 0.20 to 39.99% ± 0.47 with the increase of concentrations.

Western Blot Analysis[1]

Cell Line: HepG2
Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL
Incubation Time: 24 h
Result: Reduced the expression of procaspase-3, PARP1, procaspases-8 and -9, and Bcl-2 at 2-6 μg/mL.
Increased caspase-3, 8, 9, PARP1 cleaved and Bax protein levels.
In Vivo

Peiminine (3mg/kg, intraperitoneal injection, single dose) alleviates inflammatory manifestations and mitigates intestinal tissue damage in an experimental model of ulcerative colitis[2].
Peiminine (10 mg/kg, Intraperitoneal injection, once every 2 days for 6 weeks) prevents bone loss and fat formation in OVX-induced rat model[3].
Peiminine (1-5 mg/kg, are applied to the dorsal skin, once daily for 16 days) inhibits serum IL-6 and TNF-α in the dinitrochlorobenzene (DNCB)-induced Allergic dermatitis animal model[4].
Peiminine (2-5 mg/kg, Intraperitoneal injection, once a day for 4 weeks) has a cardioprotective effect against myocardial infarction-induced myocardial injury and fibrosis in myocardial infarction rat model[5].
Peiminine (1-5 mg/kg, Intraperitoneal injection, single dose) can reduce the damage of inflammatory response to the body and the possibility of pulmonary edema in LPS-induced Acute lung injury model mice[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ulcerative colitis model[2]
Dosage: 3mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Reduced inflammation, mucosal ulcers, involvement of digestive system layers, and infltration of inflammatory cells.
Reduced the levels of MPO and NO generated in the rectal tissue.
Reduced cell proliferation in spleen cell.
Decreased the production of f IL-1β, IL-6, and TNF-α cytokines.
Reduced expression levels of genes IL-1β, IL-6, TNF-α, iNOS, and COX2.
Animal Model: Ovariectomized (OVX) rat model[3]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Alleviated the bone loss caused by surgical castration.
Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone.
Animal Model: Allergic dermatitis model[4]
Dosage: 1 mg/kg, 5 mg/kg
Administration: were applied to the dorsal skin
Result: Alleviated the bone loss caused by surgical castration.
Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone.
Molecular Weight

429.64

Formula

C27H43NO3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

[H][C@]12[C@]3([H])CC([C@@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])C[C@]([H])1[C@]5([H])CN6C[C@@H](C)CC[C@]([H])6[C@@](C)(O)[C@]([H])5CC2)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (232.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3275 mL 11.6376 mL 23.2753 mL
5 mM 0.4655 mL 2.3275 mL 4.6551 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.94%

COA (258 KB) RP-HPLC (132 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3275 mL 11.6376 mL 23.2753 mL 58.1882 mL
5 mM 0.4655 mL 2.3275 mL 4.6551 mL 11.6376 mL
10 mM 0.2328 mL 1.1638 mL 2.3275 mL 5.8188 mL
15 mM 0.1552 mL 0.7758 mL 1.5517 mL 3.8792 mL
20 mM 0.1164 mL 0.5819 mL 1.1638 mL 2.9094 mL
25 mM 0.0931 mL 0.4655 mL 0.9310 mL 2.3275 mL
30 mM 0.0776 mL 0.3879 mL 0.7758 mL 1.9396 mL
40 mM 0.0582 mL 0.2909 mL 0.5819 mL 1.4547 mL
50 mM 0.0466 mL 0.2328 mL 0.4655 mL 1.1638 mL
60 mM 0.0388 mL 0.1940 mL 0.3879 mL 0.9698 mL
80 mM 0.0291 mL 0.1455 mL 0.2909 mL 0.7274 mL
100 mM 0.0233 mL 0.1164 mL 0.2328 mL 0.5819 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Peiminine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Peiminine18059-10-4Verticinone RaddeanineAutophagyCaspaseBcl-2 FamilyPARPp38 MAPKERKNF-κBApoptosispoly ADP ribose polymerase Extracellular signal regulated kinasesNuclear factor-κBNuclear factor-kappaBHelaHepG2SW480MCF-7Ulcerative colitisOvariectomized ratanti-inflammatoryanticanceranti-osteoporosiscardioprotectiveInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Peiminine
Cat. No.:
HY-N0213
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.